15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Entrada Therapeutics Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $17.00 to $17.00, so the covering firms are broadly aligned. The average target of $17.00 sits 192% above the current $5.83. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.94 next quarter toward $-3.26 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Entrada Therapeutics Inc.
As of Jul, 2 of 3 firms rate TRDA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TRDA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.94
Range $-1.18 – $-0.63 · 7 analysts · -11% YoY
Next period, 7 analysts expect Entrada Therapeutics Inc to earn $-0.94 a share (range $-1.18 – $-0.63), versus $-1.06 a year earlier. Full-year consensus is $-3.79, growing to $-3.26 the year after.
REVENUE · NEXT QUARTER
$7.0M
Range $0 – $25.0M · 7 analysts · +333% YoY
Revenue is expected to reach $7.0M (range $0 – $25.0M), +332.7% year-over-year. Full-year consensus is $15.0M, rising to $29.8M next year.
Top analysts covering Entrada Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TRDA.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Hold
No targeton TRDA
Overall win rate
37%
+ Follow
#2
Debjit Chattopadhyay
Guggenheim
Buy
$17.00+191.6% to target
Coverage
—
+ Follow
#3
MM
Myles Minter
William Blair
Buy
No targeton TRDA
Coverage
—
+ Follow
#4
Joseph Thome
TD Cowen
Buy
No targeton TRDA
Coverage
—
+ Follow
#5
JM
Jonathan Miller
Evercore ISI
Buy
$25.00+328.8% to target
Coverage
—
+ Follow
TRDA stock forecast FAQ
What is TRDA's average 12-month price target?+
The 1 analysts with a live target average $17.00 for Entrada Therapeutics Inc over the next 12 months, ranging from a $17.00 high to a $17.00 low.
Is TRDA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover TRDA?+
3 analysts have an active rating on Entrada Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering TRDA?+
Among analysts who currently cover TRDA, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #249). Their current call is Hold.
What is Entrada Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.94 per share (range $-1.18 – $-0.63) across 7 analysts. Full-year EPS is projected at $-3.79, rising to $-3.26 the following year.
How much revenue is Entrada Therapeutics Inc expected to report next quarter?+
Consensus revenue is $7.0M (range $0 – $25.0M). Full-year revenue is projected at $15.0M, growing to $29.8M next year.
Have analysts been upgrading or downgrading TRDA lately?+
As of Jul, 2 of 3 firms rate TRDA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TRDA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
